Browse PODXL

Summary
SymbolPODXL
Namepodocalyxin-like
Aliases PCLP; Gp200; PCLP-1; GCTM-2 antigen; podocalyxin-like protein 1; Podocalyxin
Chromosomal Location7q32-q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Apical cell membrane. Cell projection, lamellipodium. Cell projection, filopodium. Cell projection, ruffle. Cell projection, microvillus Membrane raft Membrane Single-pass type I membrane protein Note=In single attached epithelial cells is restricted to a preapical pole on the free plasma membrane whereas other apical and basolateral proteins are not yet polarized. Colocalizes with SLC9A3R2 at the apical plasma membrane during epithelial polarization. Colocalizes with SLC9A3R1 at the trans-Golgi network (transiently) and at the apical plasma membrane. Its association with the membrane raft is transient. Colocalizes with actin filaments, EZR and SLC9A3R1 in a punctate pattern at the apical cell surface where microvilli form. Colocalizes with EZR and SLC9A3R2 at the apical cell membrane of glomerular epithelium cells (By similarity). Forms granular, punctuated pattern, forming patches, preferentially adopting a polar distribution, located on the migrating poles of the cell or forming clusters along the terminal ends of filipodia establishing contact with the endothelial cells. Colocalizes with the submembrane actin of lamellipodia, particularly associated with ruffles. Colocalizes with vinculin at protrusions of cells. Colocalizes with ITGB1. Colocalizes with PARD3, PRKCI, EXOC5, OCLN, RAB11A and RAB8A in apical membrane initiation sites (AMIS) during the generation of apical surface and luminogenesis (By similarity).
Domain PF06365 CD34/Podocalyxin family
Function

Involved in the regulation of both adhesion and cell morphology and cancer progression. Function as an anti-adhesive molecule that maintains an open filtration pathway between neighboring foot processes in the podocyte by charge repulsion. Acts as a pro-adhesive molecule, enhancing the adherence of cells to immobilized ligands, increasing the rate of migration and cell-cell contacts in an integrin-dependent manner. Induces the formation of apical actin-dependent microvilli. Involved in the formation of a preapical plasma membrane subdomain to set up initial epithelial polarization and the apical lumen formation during renal tubulogenesis. Plays a role in cancer development and aggressiveness by inducing cell migration and invasion through its interaction with the actin-binding protein EZR. Affects EZR-dependent signaling events, leading to increased activities of the MAPK and PI3K pathways in cancer cells.

> Gene Ontology
 
Biological Process GO:0001655 urogenital system development
GO:0001822 kidney development
GO:0002064 epithelial cell development
GO:0007162 negative regulation of cell adhesion
GO:0022407 regulation of cell-cell adhesion
GO:0022408 negative regulation of cell-cell adhesion
GO:0022409 positive regulation of cell-cell adhesion
GO:0030031 cell projection assembly
GO:0030033 microvillus assembly
GO:0030335 positive regulation of cell migration
GO:0032528 microvillus organization
GO:0032530 regulation of microvillus organization
GO:0032534 regulation of microvillus assembly
GO:0032835 glomerulus development
GO:0033627 cell adhesion mediated by integrin
GO:0033628 regulation of cell adhesion mediated by integrin
GO:0033630 positive regulation of cell adhesion mediated by integrin
GO:0033631 cell-cell adhesion mediated by integrin
GO:0033632 regulation of cell-cell adhesion mediated by integrin
GO:0033634 positive regulation of cell-cell adhesion mediated by integrin
GO:0035148 tube formation
GO:0035239 tube morphogenesis
GO:0035850 epithelial cell differentiation involved in kidney development
GO:0040017 positive regulation of locomotion
GO:0045785 positive regulation of cell adhesion
GO:0050900 leukocyte migration
GO:0051272 positive regulation of cellular component movement
GO:0060491 regulation of cell projection assembly
GO:0060562 epithelial tube morphogenesis
GO:0061005 cell differentiation involved in kidney development
GO:0061318 renal filtration cell differentiation
GO:0072001 renal system development
GO:0072006 nephron development
GO:0072009 nephron epithelium development
GO:0072010 glomerular epithelium development
GO:0072015 glomerular visceral epithelial cell development
GO:0072073 kidney epithelium development
GO:0072112 glomerular visceral epithelial cell differentiation
GO:0072175 epithelial tube formation
GO:0072310 glomerular epithelial cell development
GO:0072311 glomerular epithelial cell differentiation
GO:2000147 positive regulation of cell motility
Molecular Function -
Cellular Component GO:0001726 ruffle
GO:0005902 microvillus
GO:0016324 apical plasma membrane
GO:0030027 lamellipodium
GO:0030175 filopodium
GO:0031252 cell leading edge
GO:0031253 cell projection membrane
GO:0031528 microvillus membrane
GO:0036056 filtration diaphragm
GO:0036057 slit diaphragm
GO:0044297 cell body
GO:0045121 membrane raft
GO:0045177 apical part of cell
GO:0098589 membrane region
GO:0098857 membrane microdomain
GO:0098858 actin-based cell projection
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolPODXL
Namepodocalyxin-like
Aliases PCLP; Gp200; PCLP-1; GCTM-2 antigen; podocalyxin-like protein 1; Podocalyxin
Chromosomal Location7q32-q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between PODXL and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolPODXL
Namepodocalyxin-like
Aliases PCLP; Gp200; PCLP-1; GCTM-2 antigen; podocalyxin-like protein 1; Podocalyxin
Chromosomal Location7q32-q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of PODXL in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolPODXL
Namepodocalyxin-like
Aliases PCLP; Gp200; PCLP-1; GCTM-2 antigen; podocalyxin-like protein 1; Podocalyxin
Chromosomal Location7q32-q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of PODXL in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.9440.032
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.8330.61
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-1.0190.37
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.6640.0177
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.5670.781
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.7840.753
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.7220.169
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.6570.678
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.8120.641
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.2990.477
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 282.7270.285
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.2790.0123
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of PODXL in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277302.7-2.71
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275903.4-3.41
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)2117011.8-11.80.193
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)1311018.2-18.20.199
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.63.7-1.11
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221307.7-7.70.371
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolPODXL
Namepodocalyxin-like
Aliases PCLP; Gp200; PCLP-1; GCTM-2 antigen; podocalyxin-like protein 1; Podocalyxin
Chromosomal Location7q32-q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PODXL. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolPODXL
Namepodocalyxin-like
Aliases PCLP; Gp200; PCLP-1; GCTM-2 antigen; podocalyxin-like protein 1; Podocalyxin
Chromosomal Location7q32-q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PODXL. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PODXL.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolPODXL
Namepodocalyxin-like
Aliases PCLP; Gp200; PCLP-1; GCTM-2 antigen; podocalyxin-like protein 1; Podocalyxin
Chromosomal Location7q32-q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PODXL. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolPODXL
Namepodocalyxin-like
Aliases PCLP; Gp200; PCLP-1; GCTM-2 antigen; podocalyxin-like protein 1; Podocalyxin
Chromosomal Location7q32-q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of PODXL expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolPODXL
Namepodocalyxin-like
Aliases PCLP; Gp200; PCLP-1; GCTM-2 antigen; podocalyxin-like protein 1; Podocalyxin
Chromosomal Location7q32-q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between PODXL and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolPODXL
Namepodocalyxin-like
Aliases PCLP; Gp200; PCLP-1; GCTM-2 antigen; podocalyxin-like protein 1; Podocalyxin
Chromosomal Location7q32-q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting PODXL collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.